Stock comparison
Haemonetics
Sotera Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
SHC
Sotera Health
Market cap
$4.47B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | SHC | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 58D | HAE |
| Benjamin Graham | 85A | 84D | HAE |
| Philip Fisher | 60C | 53C | HAE |
| Peter Lynch | 54C | 36D | HAE |
| Joel Greenblatt | 31F | 30F | HAE |
| Charlie Munger | 54D | 60D | SHC |
| Terry Smith | 55D | 58D | SHC |
Side-by-side metrics
| Metric | HAE | SHC |
|---|---|---|
| Market cap | $2.98B | $4.47B |
| P/E (TTM) | 24.8x | 36.9x |
| EV/EBIT | 14.1x | 16.1x |
| ROIC (TTM) | 8.37% | 7.96% |
| Gross margin | 55.74% | 55.01% |
| Net margin | 7.29% | 9.91% |
| Revenue CAGR 5y | 7.65% | 5.72% |
| EPS CAGR 5y | 24.62% | -9.92% |
| Debt / Equity | 1.5x | 3.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -9.92%+140%
- Debt / Equity1.5xvs 3.6x+58%
- P/E (TTM)24.8xvs 36.9x+33%
- Revenue CAGR 5y7.65%vs 5.72%+25%
SHC leads on
- Market cap$4.47Bvs $2.98B+33%
- Net margin9.91%vs 7.29%+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.